[乳酸脱氢酶与CD163阳性肿瘤相关巨噬细胞对弥漫性大B细胞淋巴瘤患者的预后价值]
[Prognostic Value of LMR and CD163TAM for Patients with Diffuse Large B Cell Lymphoma].
作者信息
Xu Xue, Ye Zong-Yuan
机构信息
Department of Pathology, Hefei First People's Hospital, Hefei 230061, Anhui Province, China.
Department of Pathology, Hefei First People's Hospital, Hefei 230061, Anhui Province, China.E-mail:
出版信息
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Aug;32(4):1091-1096. doi: 10.19746/j.cnki.issn.1009-2137.2024.04.018.
OBJECTIVE
To investigate the prognostic value of lymphocyte-to-monocyte ratio (LMR) and CD163tumor-associated macrophages (TAM) in patients with diffuse large B cell lymphoma (DLBCL).
METHODS
Peripheral blood and lymph node tissues were collected from 63 newly diagnosed DLBCL patients. LMR was calculated by the number of lymphocytes and monocytes in peripheral blood from the result of blood routine examination. The level of CD163TAM in lymph nodes was detected by immunohistochemistry. The cut-off values of LMR and CD163TAM were determined by ROC curves, and the prognostic value of LMR and CD163TAM in DLBCL patients was analyzed.
RESULTS
The LMR level of 63 newly diagnosed DLBCL patients was 3.69±1.71, and the median value of CD163TAM was 26/HPF. The number of CD163TAM was negatively correlated with LMR ( =-0.58) and positively correlated with monocyte count ( =0.46). The cut-off values of LMR and CD163TAM determined by ROC curve were 2.95 and 29/HPF, respectively, and based on this, the patients were divided into low LMR group and high LMR group, as well as low CD163TAM group and high CD163TAM group. The proportion of patients with clinical stage III-IV, IPI score 3-5 and bone marrow infiltration in the low LMR group were higher than those in the high LMR group ( < 0.05). The proportion of patients with clinical stage III-IV, IPI score 3-5, elevated LDH level and bone marrow infiltration in the high CD163TAM group were higher than those in the low CD163TAM group ( < 0.05). There was a positive correlation between LMR and OS ( =0.43) and a negative correlation between CD163TAM and OS ( =-0.65). DLBCL patients with low LMR and high CD163TAM had shorter OS ( < 0.05).
CONCLUSION
Low LMR and high CD163TAM can be used as biological markers for poor prognosis of DLBCL patients.
目的
探讨淋巴细胞与单核细胞比值（LMR）及CD163肿瘤相关巨噬细胞（TAM）在弥漫性大B细胞淋巴瘤（DLBCL）患者中的预后价值。
方法
收集63例新诊断DLBCL患者的外周血和淋巴结组织。通过血常规检查结果计算外周血中淋巴细胞和单核细胞数量得出LMR。采用免疫组织化学法检测淋巴结中CD163 TAM的水平。通过ROC曲线确定LMR和CD163 TAM的截断值，并分析LMR和CD163 TAM在DLBCL患者中的预后价值。
结果
63例新诊断DLBCL患者的LMR水平为3.69±1.71，CD163 TAM的中位数为26/HPF。CD163 TAM数量与LMR呈负相关（=-0.58），与单核细胞计数呈正相关（=0.46）。ROC曲线确定的LMR和CD163 TAM的截断值分别为2.95和29/HPF，据此将患者分为低LMR组和高LMR组，以及低CD163 TAM组和高CD163 TAM组。低LMR组临床分期III-IV期、国际预后指数（IPI）评分3-5分及骨髓浸润患者的比例高于高LMR组（<0.05）。高CD163 TAM组临床分期III-IV期、IPI评分3-5分、乳酸脱氢酶（LDH）水平升高及骨髓浸润患者的比例高于低CD163 TAM组（<0.05）。LMR与总生存期（OS）呈正相关（=0.43），CD163 TAM与OS呈负相关（=-0.65）。LMR低且CD163 TAM高的DLBCL患者OS较短（<0.05）。
结论
低LMR和高CD163 TAM可作为DLBCL患者预后不良的生物学标志物。
Zotero 插件